Morgan Stanley Rates Recursion Pharmaceuticals Stock as "Equal Weight"

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is among the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Morgan Stanley gave it an “Equal Weight” rating with a $5 price target due to volatility from macroeconomic factors and clinical performance concerns. The company is streamlining operations with Q1 2025 revenue at $15 million.

In a move to focus on high-impact programs, Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) has streamlined its portfolio with a revenue increase from collaboration agreements in Q1 2025 compared to the previous year. The company aims to prioritize resources on projects with strong scientific rationale.

While RXRX shows investment potential, other AI stocks may offer better growth opportunities with less downside risk. Investors seeking undervalued AI stocks can explore options beyond RXRX. Check out our report on the best short-term AI stock for more insights.

For more information on AI stocks, analysts recommend exploring 13 Cheap AI Stocks to Buy and 11 Unstoppable Growth Stocks to Invest in. This article is originally published at Insider Monkey.

Read more at Yahoo Finance: Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating